Summary
30.09 0.59(2.00%)05/20/2024
Avidity Biosciences Inc (RNA)
Avidity Biosciences Inc (RNA)
Key Facts
1 Day | 1 Week | 1 Month | 3 Months | 6 Months | 1 Year | 5 Years | All Time |
-3.85 | 4.93 | 2.34 | 108.04 | 334.82 | 127.97 | 0.00 | -11.05 |
Last 730 data points are shown. To view all data, Upgrade to PRO plan with only $1
Trading Data | ||
Close | 25.35 | |
Open | 26.74 | |
High | 26.74 | |
Low | 24.96 | |
Volume | 578,238 | |
Change | -1.02 | |
Change % | -3.85 | |
Avg Volume (20 Days) | 692,294 | |
Volume/Avg Volume (20 Days) Ratio | 0.84 | |
52 Week Range | 4.84 - 27.66 | |
Price vs 52 Week High | -8.35% | |
Price vs 52 Week Low | 423.76% | |
Range | -5.20 | |
Gap Up/Down | -0.11 |
Fundamentals | ||
Market Capitalization (Mln) | 2,821 | |
EBIDTA | 0 | |
PE Ratio | 0.0000 | |
PEG Ratio | 0.0000 | |
WallStreet Target Price | 56.33 | |
Book Value | 8.4200 | |
Earnings Per Share | -2.4550 | |
EPS Estimate Current Quarter | -0.6800 | |
EPS Estimate Next Quarter | -0.7400 | |
EPS Estimate Current Year | -2.7200 | |
EPS Estimate Next Year | -3.1900 | |
Diluted EPS (TTM) | -2.4550 | |
Revenues | ||
Profit Marging | 0.0000 | |
Operating Marging (TTM) | -9.9623 | |
Return on asset (TTM) | -0.1551 | |
Return on equity (TTM) | -0.2678 | |
Revenue TTM | 9,616,000 | |
Revenue per share TTM | 0.2470 | |
Quarterly Revenue Growth (YOY) | 0.2390 | |
Quarterly Earnings Growth (YOY) | 0.0000 | |
Gross Profit (TTM) | -30,815,000 |
Dividends | ||
Dividend Share | 0.0000 | |
Dividend Yield | ||
Valuations | ||
Trailing PE | 0.0000 | |
Forward PE | 0.0000 | |
Price Sales (TTM) | 0.0000 | |
Price Book (MRQ) | 2.8943 | |
Revenue Enterprise Value | 75.9910 | |
EBITDA Enterprise Value | 0.0000 | |
Shares | ||
Shares Outstanding | 46,897,100 | |
Shares Float | 35,752,929 | |
Shares Short | 0 | |
Shares Short (Prior Month) | 0 | |
Shares Ratio | 0.00 | |
Short Outstanding (%) | 0.00 | |
Short Float (%) | 0.00 | |
Insider (%) | 8.80 | |
Institutions (%) | 95.58 |
05/19 11:23 EST - seekingalpha.com
Avidity Biosciences: Strong Buy With Promising RNA Therapeutics Pipeline
Avidity Biosciences specializes in targeted RNA therapeutics using its AOC platform. Their most advanced drug candidate, del-desiran, shows promising results in clinical trials for myotonic DM1. The company has achieved significant milestones, including FDA breakthrough therapy status and positive trial results, increasing the likelihood of FDA approval.
Avidity Biosciences: Strong Buy With Promising RNA Therapeutics Pipeline
Avidity Biosciences specializes in targeted RNA therapeutics using its AOC platform. Their most advanced drug candidate, del-desiran, shows promising results in clinical trials for myotonic DM1. The company has achieved significant milestones, including FDA breakthrough therapy status and positive trial results, increasing the likelihood of FDA approval.
05/15 09:00 EST - prnewswire.com
Avidity Biosciences Announces Appointment of Simona Skerjanec to Board of Directors
SAN DIEGO , May 15, 2024 /PRNewswire/ -- Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide Conjugates (AOCs™), today announced the appointment of Simona Skerjanec, M.Pharm, MBA to its board of directors. Ms. Skerjanec brings nearly three decades of global experience in the pharmaceutical industry with a strong track record in developing and launching therapies, as well as shaping corporate strategy to deliver transformative treatments to people living with serious diseases.
Avidity Biosciences Announces Appointment of Simona Skerjanec to Board of Directors
SAN DIEGO , May 15, 2024 /PRNewswire/ -- Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide Conjugates (AOCs™), today announced the appointment of Simona Skerjanec, M.Pharm, MBA to its board of directors. Ms. Skerjanec brings nearly three decades of global experience in the pharmaceutical industry with a strong track record in developing and launching therapies, as well as shaping corporate strategy to deliver transformative treatments to people living with serious diseases.
05/09 16:05 EST - prnewswire.com
Avidity Biosciences Reports First Quarter 2024 Financial Results and Recent Highlights
Initiation of global Phase 3 HARBOR™ trial for del-desiran (AOC 1001) in DM1 on track for this quarter Avidity to report FSHD data from FORTITUDE™ trial this quarter and DMD data from EXPLORE44™ trial in 2H24 Presented positive long-term del-desiran data from MARINA-OLE™ showing reversal of disease progression in people living with myotonic dystrophy type 1 across multiple endpoints; same key endpoints, with vHOT as primary, agreed for phase 3 HARBOR trial Cash position of $915 million at the end of Q124 following successful private placement SAN DIEGO , May 9, 2024 /PRNewswire/ -- Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide Conjugates (AOCs™), today reported financial results for the first quarter ended March 31, 2024, and highlighted recent corporate progress. "As we move forward with the planned initiation of our global Phase 3 HARBOR™ study for del-desiran this quarter, we continue to work diligently to improve people's lives by advancing our AOC platform," said Sarah Boyce, president and chief executive officer at Avidity.
Avidity Biosciences Reports First Quarter 2024 Financial Results and Recent Highlights
Initiation of global Phase 3 HARBOR™ trial for del-desiran (AOC 1001) in DM1 on track for this quarter Avidity to report FSHD data from FORTITUDE™ trial this quarter and DMD data from EXPLORE44™ trial in 2H24 Presented positive long-term del-desiran data from MARINA-OLE™ showing reversal of disease progression in people living with myotonic dystrophy type 1 across multiple endpoints; same key endpoints, with vHOT as primary, agreed for phase 3 HARBOR trial Cash position of $915 million at the end of Q124 following successful private placement SAN DIEGO , May 9, 2024 /PRNewswire/ -- Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide Conjugates (AOCs™), today reported financial results for the first quarter ended March 31, 2024, and highlighted recent corporate progress. "As we move forward with the planned initiation of our global Phase 3 HARBOR™ study for del-desiran this quarter, we continue to work diligently to improve people's lives by advancing our AOC platform," said Sarah Boyce, president and chief executive officer at Avidity.
05/08 16:05 EST - prnewswire.com
Avidity Biosciences to Participate in Upcoming Investor Conference
SAN DIEGO , May 8, 2024 /PRNewswire/ -- Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide Conjugates (AOCs™), today announced that Avidity management will be participating in the following upcoming conference: BofA Securities 2024 Health Care Conference on May 15 at 8:00 a.m. PT / 11:00 a.m.
Avidity Biosciences to Participate in Upcoming Investor Conference
SAN DIEGO , May 8, 2024 /PRNewswire/ -- Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide Conjugates (AOCs™), today announced that Avidity management will be participating in the following upcoming conference: BofA Securities 2024 Health Care Conference on May 15 at 8:00 a.m. PT / 11:00 a.m.
04/22 16:05 EST - prnewswire.com
Avidity Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
SAN DIEGO , April 22, 2024 /PRNewswire/ -- Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide Conjugates (AOCs™), today announced that on April 20, 2024, the Human Capital Management Committee of Avidity's Board of Directors granted non-qualified stock option awards to purchase an aggregate of 37,500 shares of its common stock and 18,750 restricted stock units ("RSUs") to three (3) new non-executive employees under the Avidity Biosciences, Inc. 2022 Employment Inducement Incentive Award Plan (the "2022 Inducement Plan"). The awards were granted as inducements material to the employees entering into employment with Avidity in accordance with Nasdaq Listing Rule 5635(c)(4).
Avidity Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
SAN DIEGO , April 22, 2024 /PRNewswire/ -- Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide Conjugates (AOCs™), today announced that on April 20, 2024, the Human Capital Management Committee of Avidity's Board of Directors granted non-qualified stock option awards to purchase an aggregate of 37,500 shares of its common stock and 18,750 restricted stock units ("RSUs") to three (3) new non-executive employees under the Avidity Biosciences, Inc. 2022 Employment Inducement Incentive Award Plan (the "2022 Inducement Plan"). The awards were granted as inducements material to the employees entering into employment with Avidity in accordance with Nasdaq Listing Rule 5635(c)(4).
03/27 09:00 EST - prnewswire.com
Avidity Biosciences to Participate in Upcoming Investor Conferences
SAN DIEGO , March 27, 2024 /PRNewswire/ -- Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide Conjugates (AOCs™), today announced that Avidity management will be participating in the following upcoming conferences: Cantor Fitzgerald Virtual Muscular Dystrophy Symposium on April 3 at 9:40 a.m. PT/ 12:40 p.m.
Avidity Biosciences to Participate in Upcoming Investor Conferences
SAN DIEGO , March 27, 2024 /PRNewswire/ -- Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide Conjugates (AOCs™), today announced that Avidity management will be participating in the following upcoming conferences: Cantor Fitzgerald Virtual Muscular Dystrophy Symposium on April 3 at 9:40 a.m. PT/ 12:40 p.m.
03/05 14:48 EST - seekingalpha.com
Dyne: H2 2024 Muscle Disease Data Could Boost Value
Dyne Therapeutics, Inc. results from the phase 1/2 ACHIEVE study, using DYNE-101 for the treatment of patients with Myotonic Dystrophy Type 1, expected in H2 2024. The Myotonic Dystrophy Type 1 treatment market is expected to reach $2.78 billion by 2033.
Dyne: H2 2024 Muscle Disease Data Could Boost Value
Dyne Therapeutics, Inc. results from the phase 1/2 ACHIEVE study, using DYNE-101 for the treatment of patients with Myotonic Dystrophy Type 1, expected in H2 2024. The Myotonic Dystrophy Type 1 treatment market is expected to reach $2.78 billion by 2033.
03/04 11:35 EST - investors.com
Top 2% Biotech Avidity Collapses Despite 'Positive' Results In Treating Muscular Dystrophy
Top-notch biotech stock Avidity collapsed Monday despite unveiling "positive" midstage test results for its muscular dystrophy treatment.
Top 2% Biotech Avidity Collapses Despite 'Positive' Results In Treating Muscular Dystrophy
Top-notch biotech stock Avidity collapsed Monday despite unveiling "positive" midstage test results for its muscular dystrophy treatment.
02/29 13:39 EST - seekingalpha.com
Avidity Biosciences: DMD Advancement And 2024 Catalysts Make It A Must-Watch
Avidity Biosciences: DMD Advancement And 2024 Catalysts Make It A Must-Watch
Avidity Biosciences: DMD Advancement And 2024 Catalysts Make It A Must-Watch
Avidity Biosciences: DMD Advancement And 2024 Catalysts Make It A Must-Watch
02/29 12:00 EST - prnewswire.com
Avidity Biosciences Honors Rare Disease Day®
SAN DIEGO , Feb. 29, 2024 /PRNewswire/ -- Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide Conjugates (AOCs™), today announced its support for Rare Disease Day®, highlighting the importance of bringing awareness to the devastating impact rare diseases have on patients, families and caregivers worldwide. "Today, on Rare Disease Day, we are proud to join the global community in raising awareness for people living with rare diseases," said Sarah Boyce, president and chief executive officer at Avidity.
Avidity Biosciences Honors Rare Disease Day®
SAN DIEGO , Feb. 29, 2024 /PRNewswire/ -- Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide Conjugates (AOCs™), today announced its support for Rare Disease Day®, highlighting the importance of bringing awareness to the devastating impact rare diseases have on patients, families and caregivers worldwide. "Today, on Rare Disease Day, we are proud to join the global community in raising awareness for people living with rare diseases," said Sarah Boyce, president and chief executive officer at Avidity.
02/29 07:00 EST - prnewswire.com
Avidity Biosciences Announces Oversubscribed $400 Million Private Placement
Funding from new and existing investors, including Adage Capital Partners LP, Boxer Capital, Casdin Capital, LLC, Farallon, Janus Henderson Investors, RA Capital Management, RTW Investments, Wellington Management, as well as multiple large investment management firms Pro forma cash, cash equivalents and investments expected to provide runway into late 2026 Avidity to host Volume 8 of investor and analyst event series via webcast March 4, 2024, at 8:00 a.m. ET to present AOC 1001 data from MARINA-OLE™ SAN DIEGO , Feb. 29, 2024 /PRNewswire/ -- Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide Conjugates (AOCs™), today announced that it has agreed to sell 15,224,773 shares of its common stock at a price of $16.50 per share and pre-funded warrants to purchase 9,030,851 shares of its common stock at a price per pre-funded warrant of $16.4990 to a select group of institutional and accredited healthcare specialist investors in an oversubscribed private placement.
Avidity Biosciences Announces Oversubscribed $400 Million Private Placement
Funding from new and existing investors, including Adage Capital Partners LP, Boxer Capital, Casdin Capital, LLC, Farallon, Janus Henderson Investors, RA Capital Management, RTW Investments, Wellington Management, as well as multiple large investment management firms Pro forma cash, cash equivalents and investments expected to provide runway into late 2026 Avidity to host Volume 8 of investor and analyst event series via webcast March 4, 2024, at 8:00 a.m. ET to present AOC 1001 data from MARINA-OLE™ SAN DIEGO , Feb. 29, 2024 /PRNewswire/ -- Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide Conjugates (AOCs™), today announced that it has agreed to sell 15,224,773 shares of its common stock at a price of $16.50 per share and pre-funded warrants to purchase 9,030,851 shares of its common stock at a price per pre-funded warrant of $16.4990 to a select group of institutional and accredited healthcare specialist investors in an oversubscribed private placement.
02/28 18:20 EST - zacks.com
Avidity Biosciences, Inc. (RNA) Reports Q4 Loss, Misses Revenue Estimates
Avidity Biosciences, Inc. (RNA) came out with a quarterly loss of $0.79 per share versus the Zacks Consensus Estimate of a loss of $0.54. This compares to loss of $0.88 per share a year ago.
Avidity Biosciences, Inc. (RNA) Reports Q4 Loss, Misses Revenue Estimates
Avidity Biosciences, Inc. (RNA) came out with a quarterly loss of $0.79 per share versus the Zacks Consensus Estimate of a loss of $0.54. This compares to loss of $0.88 per share a year ago.
02/26 06:55 EST - investorplace.com
3 Highly Rated Biotech Stocks to Buy for 300% Gains
Investors know that the world of biotech stocks is home to a great percentage of opportunities that can triple and quadruple their capital. It's also fairly easy to identify such stocks using screener tools that can tease out such opportunities.
3 Highly Rated Biotech Stocks to Buy for 300% Gains
Investors know that the world of biotech stocks is home to a great percentage of opportunities that can triple and quadruple their capital. It's also fairly easy to identify such stocks using screener tools that can tease out such opportunities.
01/29 09:56 EST - zacks.com
Strength Seen in Avidity Biosciences, Inc. (RNA): Can Its 15.0% Jump Turn into More Strength?
Avidity Biosciences, Inc. (RNA) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
Strength Seen in Avidity Biosciences, Inc. (RNA): Can Its 15.0% Jump Turn into More Strength?
Avidity Biosciences, Inc. (RNA) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
01/05 08:30 EST - prnewswire.com
Avidity Biosciences Announces 2024 Corporate Priorities and Catalysts for Next Stage of Growth
Avidity plans to initiate global Phase 3 HARBOR ™ trial of AOC 1001 for DM1 mid-2024 Company to report data from all three ongoing clinical programs in 2024 -- AOC 1001 data for DM1 in Q1, AOC 1020 data for FSHD in Q2, and AOC 1044 data for DMD44 in 2H -- Avidity to advance wholly-owned and partnered cardiology programs toward clinical development Avidity appoints Eric B. Mosbrooker as Chief Strategy Officer SAN DIEGO , Jan. 5, 2024 /PRNewswire/ -- Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide Conjugates (AOCs™), today announced its 2024 corporate priorities and catalysts for the next stage of growth.
Avidity Biosciences Announces 2024 Corporate Priorities and Catalysts for Next Stage of Growth
Avidity plans to initiate global Phase 3 HARBOR ™ trial of AOC 1001 for DM1 mid-2024 Company to report data from all three ongoing clinical programs in 2024 -- AOC 1001 data for DM1 in Q1, AOC 1020 data for FSHD in Q2, and AOC 1044 data for DMD44 in 2H -- Avidity to advance wholly-owned and partnered cardiology programs toward clinical development Avidity appoints Eric B. Mosbrooker as Chief Strategy Officer SAN DIEGO , Jan. 5, 2024 /PRNewswire/ -- Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide Conjugates (AOCs™), today announced its 2024 corporate priorities and catalysts for the next stage of growth.